Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V1KS
|
|||
| Former ID |
DIB011928
|
|||
| Drug Name |
AZD-2836
|
|||
| Synonyms |
A-00060058; A-00060617; A-48504; A-48756; A-48773; A-831; HCV NS5A inhibitors, Arrow Therapeutics; Hepatitis C virus therapeutics (NS5A inhibitors), Arrow
Click to Show/Hide
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1/2 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus Non-structural 5A (HCV NS5A) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00522808) A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers. U.S. National Institutes of Health. | |||
| REF 2 | TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.